# A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

> **NCT00132678** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 559 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Risperdal Consta
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00132678
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2007-10
- **Final completion:** 2007-12
- **Target enrollment:** 559 (ACTUAL)
- **Last updated:** 2013-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132678, "A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00132678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*